| Literature DB >> 35696143 |
Xiaoqi Tao1,2, Yuanyuan Peng1, Juewen Liu2.
Abstract
Veterinary drugs have been widely used in the food industry. Their residues in food products need to be tightly regulated to ensure food safety. In particular, some veterinary drugs are still used illegally, although they have already been banned. Nanomaterials are playing an increasingly important role in analytical chemistry due to their unique properties. Compared to traditional organic dyes and colloidal gold nanoparticle labels, fluorescent nanomaterials appear particularly attractive for the detection of veterinary drug residues. This review summarizes recent advancements of fluorescent biosensors using nanomaterials for the detection of veterinary drug residues in foods. The useful properties of each type of fluorescent nanomaterial are first discussed such as large Stokes shifts, long emission lifetime, and high quantum yields, which are useful for detection in food-related sample matrix. The following target recognition molecules are then reviewed individually including antibodies, aptamers, molecularly imprinted polymers, and metal ion coordination based ligands. Representative bioconjugation and assay methods are discussed for each recognition mechanism. Finally, a few future research directions are outlined in the last section of this review.Entities:
Year: 2020 PMID: 35696143 PMCID: PMC9261812 DOI: 10.38212/2224-6614.1267
Source DB: PubMed Journal: J Food Drug Anal Impact factor: 6.157
Fig. 1Structures of some common veterinary drugs: (a) antibiotics, (b) synthetic antibacterials, (c) antiparasitic drugs, (d) growth-promoting agents.
Common food sample pretreatment for biosensors.
| Methods | Advantages | Disadvantages |
|---|---|---|
| Nitrogen blowing |
Concentration without oxygen Time-saving Easy to operate and control | Suitable only for small volume or size of samples |
| Immunoaffinity chromatography (IAC) | High selectivity and stability | Complicated preparation of antibodies |
| Solid-phase extraction (SPE) |
Time-saving Achieving the trace separation High selectivity and reproducibility |
High cost of SPE columns Need professional operators |
| Rotary evaporation |
Flash distillation Suitable for bulk sample concentration | Boiling may occur, resulting in a loss of samples. |
Fig. 2Schematic illustration of various fluorescent nanoparticles for the detection of veterinary drugs: (a) fluorescent microspheres; (b) quantum dots; and (c) metal nanoclusters.
Fig. 3(a) The extraction of useful fluorescence signals from nonspecific background fluorescence with the help of a time delay. (b) Ultraviolet to visible light emitted by UCNPs under near-infrared light excitation.
Overview of fluorescent immunosensing platforms using nanomaterials for veterinary drug detection.
| Type | Analyte | Sample | Labelling Methods | Detection limit | Ref. |
|---|---|---|---|---|---|
| FLISA | Quinolones | Milk | Carboxylate-modified QD655 labelled secondary antibody | 0.18 μg L−1 | [ |
| Sulfonamides | Avidin coated QD605-biotinylated primary antibody | 0.17 μg L−1 | |||
| Melamine | 7.5 μg L−1 | ||||
| FLISA | Sulfamethazine | Chicken muscle tissue | Carboxylate-modified QD655 labelled secondary antibody | 1.0 μg L−1 | [ |
| FLISA | Enrofloxacin | Chicken muscle tissue | Carboxylate-modified QD655 labelled secondary antibody | 2.5 μg L−1 | [ |
| FLISA | Tylosin | Edible animal tissues | Carboxylate-modified QD655 labelled secondary antibody | 0.02 μg L−1 | [ |
| Tilmicosin | 0.04 μg kg−1 | ||||
| FIA | Norfloxacin | Animal-derived foods | Carboxyl-modified NaYF4:Yb,Tm UNCPs labelled anti-target MAb | 0.01 μg L−1 | [ |
| FIA | Sulfaquinoxaline | Animal-derived foods | Carboxyl-modified NaYF4:Yb,Tm UNCPs labelled anti-target MAb | 0.5 μg kg−1 | [ |
| FICA | Kanamycin | Milk | BHHCT-Eu3+@ SiO2 labelled anti-target MAb (glutaraldehyde crosslinking) | 0.85 μg L−1 | [ |
| FICA | Sulfamethazine | Honey | Carboxyl groups on AIEFM labelled anti-target MAb | 0.028 μg L−1 | [ |
| FICA | Enrofloxacin | Animal tissue | Carboxylate-modified ZnCdSe/ZnS QDs labelled anti-target MAb | 5 μg kg−1 | [ |
| Milk | Carboxylate-modified dyed polymer microsphere labelled antitarget MAb | 10 μg L−1 | |||
| FICA | Ractopamine | Swine urine | Carboxylate-modified time-resolved fluorescent nanobeads labelled anti-target PAb | 7.2 ng L−1 | [ |
| Fluorescent submicrospheres labelled anti-target PAb | 0.0147 μg L−1 | ||||
| Carboxylate-modified QDs labelled anti-target PAb | 0.0236 μg L−1 | ||||
| FICA | Clenbuterol | Swine urine | Carboxylate-modified Fluorescent magnetic nanobeads labelled anti-target MAb 0.22 μg L−1 | [ | |
| FICA | Lincomycin | Milk, honey, beef | Carboxylate-modified FluoSpheres® labelled anti-target MAb | 0.69 μg L−1 | [ |
| FICA | Sulfamethazine | Milk | Carboxylate-modified FluoSpheres® labelled anti-target MAb | 0.11 μg L−1 | [ |
| FICA | Tilmicosin | Milk | Carboxylate-modified FluoSpheres® labelled anti-target MAb | 0.19 μg L−1 | [ |
| FICA | Enrofloxacin | Chicken meat | Ru(phen)32+-doped FN labelled anti-target MAb (EDC crosslinking) | 0.02 μg L−1 | [ |
| FICA | Oxytetracycline | Edible animal tissues | QDs labelled anti-target MAb (EDC crosslinking) | 0.44 μg L−1 | [ |
| FICA | Gentamicin | Milk | Carboxylate-modified QDs labelled anti-target PAb | 2 μg kg−1 | [ |
| FICA | Ractopamine | Swine urine and muscle tissue | [FRET] Carboxylate-modified fluorescent polymer dots labelled | 0.16 μg L−1 | [ |
| BSA AuNPs labelled anti-target MAb act as quencher | |||||
| FICA | Tetracycline antibiotics | Milk | [FRET] Carboxylate-modified ZnCdSe/ZnS QDs labelled OVA | 20 μg L−1 | [ |
| Animal muscle tissue | AuNPs labelled anti-target MAb act as quencher | 40 μg kg−1 | |||
| MLFIA | Clenbuterol | Swine urine | Carboxyl groups on Arg/ATT/AuNCs labelled anti-target MAb | 0.25 μg L−1 | [ |
| FTIACT | Sulfonamide | Milk | Liposome-encapsulated QDs labelled with hapten-carried protein conjugates via N-succinimidyl 3-(2-pyridyldithio) propionate | 0.13 μg L−1 | [ |
| Quinolone | 0.062 μg L−1 | ||||
| FICA | Macrolides | Raw milk | Carboxylate-Modified FluoSpheres® labelled antibody | 0.13 μg L−1 | [ |
Fig. 4Schematic illustration of fluorescence-linked immunoassays for the detection of veterinary drugs: (a) direct competition; (b) indirect competition; and (c) combined with immunomagnetic separation. (d) Bioconjugation methods between antibodies and fluorescent nanoparticles.
Fig. 5Schematic illustration of fluorescent lateral flow immunoassay for veterinary drug detection: (a) traditional assay (figure created based on ref. [41]); (b) combined with immunomagnetic separation (figure created based on ref. [71]); (c) multiplex lateral flow immunoassay (figure created based on ref. [39]); (d) multiplex flow-through immunoaffinity chromatography test (figure created based on ref. [55]); (e) base on FRET (figure created based on ref. [79]).
Overview of aptamer-based fluorescent biosensors using nanomaterials for veterinary drug detection.
| Strategy | Analyte | Sample | Method | Detection limit | Ref. |
|---|---|---|---|---|---|
| Nanomaterials as fluorescence quenchers | Oxytetracycline | Honey, water | FRET from thiol-Aptamer modified AgNCs to target. | 0.046 μg L−1 | [ |
| Sulfadimethoxine | Milk | FRET from Aptamer-FAM to CPNBs. | 10 μg L−1 | [ | |
| Oxytetracycline | Lake water | FRET from Aptamer-FAM to rGO. | 4.6 μg L−1 | [ | |
| Tetracycline | Milk | FRET from Aptamer-VS2 QDs to MoS2 nanosheets. (amino-carboxyl condensation reaction between VS2 QDs and aptamer) | 0.06 μg L−1 | [ | |
| Tetracycline | Animal-derived food | FRET from Aptamer-N-GQDs to CoOOH. (amino-carboxyl condensation reaction between N-GQDs and aptamer) | 0.95 μg L−1 | [ | |
| Oxytetracycline | Tap water, river | FRET from Aptamer-FAM to GO hydrogel. | 25 μg L−1 | [ | |
| Kanamycin | Milk, animal-derived food | FRET from Aptamer-CDs to MoS2 nanosheets. (amino-carboxyl condensation reaction between CDs and aptamer) | 532.95 μg L−1 | [ | |
| Kanamycin | Milk | FRET from Aptamer-FAM to rGO. | 0.4845 ng L−1 | [ | |
| Florfenicol | Milk | FRET from Aptamer-ATTO647N to GO. | 2.06 μg L−1 | [ | |
| Oxytetracycline | Spiked milk and tablets | FRET from oxytetracycline-Eu3+ to AgNPs. (electrostatic adsorption between targets and Eu3+) | 0.874 μg L−1 | [ | |
| Kanamycin A | Milk | FRET from Aptamer-FAM to AuNPs | 0.145 μg L−1 | [ | |
| Label-free sensors | Enrofloxacin | Milk | FRET from targets to GO. | 1.33 μg L−1 | [ |
| Ofloxacin | Milk | FRET from Rhodamine B to AuNPs. | 1.66 μg L−1 | [ | |
| Kanamycin | Milk | IFE from CDs to AuNPs. | 8.72 μg L−1 | [ | |
| Direct detection [Splitting aptamers] | Kanamycin | Human serum | One DNA split was labelled with CuS nanoparticle by amino-carboxyl condensation reaction, and the other was coupled with paramagnetic particles (PMPs) by biotin-streptavidin system crosslinking. | 12.597 ng L−1 | [ |
| Indirect competitive [Strand-displacement strategy] | Kanamycin | Milk | FRET from QDs-SSB to Aptamer-BHQ1 (amino-carboxyl condensation reaction between QDs and SSB) | 0.006 μg L−1 | [ |
| Oxytetracycline | Milk | FRET from FAM (labelled on CS) to GO. | 4.6043 mg L−1 | [ | |
| Oxytetracycline | Milk | LRET from NaYF4:Yb,Tm UCNPs to SYBR Green I. (amino-carboxyl condensation reaction between UCNPs and aptamer) | 0.054 μg L−1 | [ | |
| Kanamycin | Milk, serum | FRET from FAM (labelled on CS) to AuNPs. | 0.156 μg L−1 | [ |
Fig. 6Schematic illustration of assays based on nanomaterials as fluorescence quenchers and label-free sensors for the detection of veterinary drugs. (a) Labelled type (figure created based on ref. [84,86]). (b) Label-free assay base on FRET from rhodamine B to AuNPs (figure created based on ref. [95]). (c) Label-free assay base on IFE from CDs to AuNPs (figure created based on ref. [96]). (d) Label-free assay base on the autofluorescence of target (figure created based on ref. [94]).
Fig. 7Schematic illustration of assays based on the splitting aptamers for the detection of veterinary drugs (figure created based on ref. [97]).
Fig. 8Schematic illustration of assays based on the structure-switching aptamer strategies for the detection of veterinary drugs. (a) Assays based on FRET (figure created based on ref. [52,98]). (b) Assays based on LRET (figure created based on ref. [99]). (c) Assays based on gated release of dyes from MSNs (figure created based on ref. [36]).
Overview of target recognition based on molecularly imprinted polymers or metal coordination using nanomaterials for veterinary drug detection.
| Type | Analyte | Sample | Fluorescent nanoparticles | Method | Detection limit | Ref. |
|---|---|---|---|---|---|---|
| Based on molecular imprinted polymers | Tetracycline | Milk | CDs@MIPs | CDs@MIPs composites were directly coupled to Targets (amino-carboxyl condensation reaction between CDs and MIPs) | 2.44 μg L−1 | [ |
| Enrofloxacin | Milk | MIP (synthetic antibody mimic) | Direct distinguish in situ analytes bound to the MIP from the free analyte in solution via the FPI. | 100.63 μg L−1 | [ | |
| Danofloxacin | 28.59 μg L−1 | |||||
| Based on metal coordination | Oxytetracycline hydrochloride | Milk | CDs | The fluorescence quenching of CDs is caused by Fe3+; fluorescence recovery after adding targets. | 12.12 μg L−1 | [ |
| Chlortetracycline | Milk | Au/PtNCs | Fluorescence quenching response of Au/PtNCs toward chlortetracycline. And the recovery upon Al3+ addition. | 167.61 μg L−1 | [ |
Fig. 9(a) Schematic illustration of target recognition based on MIPs for the detection of veterinary drugs (figure created based on ref. [109]). (b) Schematic illustration of target recognition based on metal coordination for the detection of veterinary drugs (figure created based on ref. [112,113]).